Allogene Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.03-15

Allogene Therapeutics (NASDAQ:ALLO) Full Year 2024 Results

Key Financial Results

Net loss: US$257.6m (loss narrowed by 21% from FY 2023).
US$1.32 loss per share (improved from US$2.09 loss in FY 2023).

ALLO Products In Clinical Trials

Phase I: 1.
Phase II: 1.

NasdaqGS:ALLO Earnings and Revenue History March 15th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Allogene Therapeutics EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 36%. Earnings per share (EPS) exceeded analyst estimates by 3.0%.

Looking ahead, revenue is forecast to grow 60% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 11% from a week ago.

Risk Analysis

We should say that we've discovered 5 warning signs for Allogene Therapeutics (2 shouldn't be ignored!) that you should be aware of before investing here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.